EP3429584A4 - Compositions et méthodes de traitement de la presbytie - Google Patents

Compositions et méthodes de traitement de la presbytie Download PDF

Info

Publication number: EP3429584A4
Authority: EP; European Patent Office
Prior art keywords: presbyopia; compositions; treatment; methods
Prior art date: 2016-03-17
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Withdrawn

Application number

EP17767172.4A

Other languages

German (de)

English (en)

Other versions

EP3429584A1 (fr

Inventor

Gerald Horn

Lee NORDAN

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Presbyopia Therapies Inc

Original Assignee

Presbyopia Therapies Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2016-03-17

Filing date

2017-03-08

Publication date

2019-11-13

2016-03-17 Priority claimed from US15/073,139 external-priority patent/US9833441B2/en

2016-03-17 Priority claimed from US15/073,089 external-priority patent/US9844537B2/en

2016-08-12 Priority claimed from US15/235,431 external-priority patent/US10052313B2/en

2017-03-08 Application filed by Presbyopia Therapies Inc filed Critical Presbyopia Therapies Inc

2019-01-23 Publication of EP3429584A1 publication Critical patent/EP3429584A1/fr

2019-11-13 Publication of EP3429584A4 publication Critical patent/EP3429584A4/fr

Status Withdrawn legal-status Critical Current

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4409—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 4, e.g. isoniazid, iproniazid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Ophthalmology & Optometry (AREA)
Engineering & Computer Science (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Oil, Petroleum & Natural Gas (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)

EP17767172.4A 2016-03-17 2017-03-08 Compositions et méthodes de traitement de la presbytie Withdrawn EP3429584A4 (fr)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US15/073,139 US9833441B2 (en)	2013-08-28	2016-03-17	Compositions and methods for the treatment of presbyopia
US15/073,089 US9844537B2 (en)	2013-08-28	2016-03-17	Compositions and methods for the treatment of presbyopia
US15/235,431 US10052313B2 (en)	2013-08-28	2016-08-12	Compositions and methods for the treatment of presbyopia
PCT/US2017/021244 WO2017160548A1 (fr)	2016-03-17	2017-03-08	Compositions et méthodes de traitement de la presbytie

Publications (2)

Publication Number	Publication Date
EP3429584A1 EP3429584A1 (fr)	2019-01-23
EP3429584A4 true EP3429584A4 (fr)	2019-11-13

Family

ID=59852351

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
EP17767172.4A Withdrawn EP3429584A4 (fr)	2016-03-17	2017-03-08	Compositions et méthodes de traitement de la presbytie

Country Status (6)

Country	Link
EP (1)	EP3429584A4 (fr)
JP (1)	JP2019508472A (fr)
CN (1)	CN108883102A (fr)
CA (1)	CA3017755A1 (fr)
MX (1)	MX2018011300A (fr)
WO (1)	WO2017160548A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US11026884B2 (en) *	2018-01-24	2021-06-08	Eye Therapies Llc	Methods for improving vision
US20190321334A1 (en) *	2018-04-19	2019-10-24	Presbyopia Therapies, LLC	Compositions and methods for the treatment of presbyopia
US11077053B2 (en)	2018-08-21	2021-08-03	Allergan, Inc.	Alpha-2-adrenergic receptor agonists for treatment of presbyopia, visual glare, visual starbursts, visual halos and night myopia
BR112021006618B1 (pt) *	2018-10-10	2022-09-27	Presbyopia Therapies, Inc	Composições e métodos para o tratamento da presbiopia
US20210251970A1 (en)	2018-10-10	2021-08-19	Presbyopia Therapies Inc	Compositions and methods for storage stable ophthalmic drugs
US20220273557A1 (en) *	2019-07-26	2022-09-01	Allergan Sales, Llc	Compositions and methods for treatment of presbyopia
CN116583277A (zh) *	2020-11-02	2023-08-11	视觉治疗股份有限公司	药物中的降解化合物
US20230390284A1 (en) *	2020-11-02	2023-12-07	Visus Therapeutics, Inc.	Degradant compound in a medicant
WO2023086878A1 (fr)	2021-11-10	2023-05-19	Visus Therapeutics, Inc.	Formulations de carbachol pour améliorer les effets anti-presbytie
US12180206B2 (en)	2021-11-17	2024-12-31	Lenz Therapeutics Operations, Inc.	Aceclidine derivatives, compositions thereof and methods of use thereof
CN114588156B (zh) *	2022-04-22	2024-06-11	温州医科大学附属眼视光医院	一种眼用制剂及其在治疗老花眼中的应用
US12414942B1 (en) *	2024-03-15	2025-09-16	Lenz Therapeutics Operations, Inc.	Compositions, methods, and systems for treating presbyopia

Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20160008278A1 (en) *	2013-08-28	2016-01-14	Presbyopia Therapies, LLC	Compositions and Methods for the Treatment of Presbyopia
US20160346259A1 (en) *	2013-08-28	2016-12-01	Presbyopia Therapies, LLC	Compositions and Methods for the Treatment of Presbyopia

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6120758A (en) *	1998-07-16	2000-09-19	Shaklee Corporation	Preservative system for topically applied products
US9314427B2 (en) *	2013-08-28	2016-04-19	Presbyopia Therapies Llc	Compositions and methods for the improvement of distance vision and the treatment of refractive errors of the eye
BR112016014404A2 (pt) *	2013-12-18	2017-08-08	Gnt Llc	Composições e métodos para tratamento de glaucoma

2017
- 2017-03-08 CA CA3017755A patent/CA3017755A1/fr not_active Abandoned
- 2017-03-08 JP JP2018548865A patent/JP2019508472A/ja active Pending
- 2017-03-08 EP EP17767172.4A patent/EP3429584A4/fr not_active Withdrawn
- 2017-03-08 CN CN201780017733.8A patent/CN108883102A/zh active Pending
- 2017-03-08 WO PCT/US2017/021244 patent/WO2017160548A1/fr not_active Ceased
- 2017-03-08 MX MX2018011300A patent/MX2018011300A/es unknown

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20160008278A1 (en) *	2013-08-28	2016-01-14	Presbyopia Therapies, LLC	Compositions and Methods for the Treatment of Presbyopia
US20160346259A1 (en) *	2013-08-28	2016-12-01	Presbyopia Therapies, LLC	Compositions and Methods for the Treatment of Presbyopia

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2017160548A1 *

Also Published As

Publication number	Publication date
CA3017755A1 (fr)	2017-09-21
WO2017160548A1 (fr)	2017-09-21
EP3429584A1 (fr)	2019-01-23
JP2019508472A (ja)	2019-03-28
CN108883102A (zh)	2018-11-23
MX2018011300A (es)	2019-02-18

Publication	Publication Date	Title
EP3429584A4 (fr)	2019-11-13	Compositions et méthodes de traitement de la presbytie
EP3177732A4 (fr)	2018-04-25	Compositions et procédés pour le traitement de maladies et états pathologiques ophthalmiques
EP3038610A4 (fr)	2017-03-22	Compositions et méthodes pour le traitement de la presbytie
EP3863630A4 (fr)	2022-06-29	Compositions et procédés pour le traitement de la presbytie
EP3183005A4 (fr)	2018-01-10	Méthodes et compositions destinées au traitement de troubles métaboliques
EP3094284A4 (fr)	2017-12-13	Compositions et méthodes pour le traitement d'une néovascularisation et/ou d'une fuite intraoculaire
EP3538189A4 (fr)	2020-04-22	Compositions, dispositifs et méthodes pour le traitement de conditions médiées par un récepteur des opioides
EP3182989A4 (fr)	2018-04-11	Méthodes et compositions destinées à prévenir et à traiter une maladie
EP3720421A4 (fr)	2021-09-15	Compositions et méthodes pour le traitement d'affections métaboliques
EP3265096A4 (fr)	2018-10-24	Compositions ophtalmiques et leurs procédés d'utilisation
EP3687524A4 (fr)	2021-06-09	Compositions et méthodes de traitement de troubles ophtalmiques
IL272121A (en)	2020-03-31	Preparation and methods for the treatment of myopia
EP3651747A4 (fr)	2020-07-22	Compositions et méthodes de traitement de troubles oculaires
ZA201902781B (en)	2019-12-18	Compositions and methods for the treatment of xerostomia
EP3310783A4 (fr)	2018-12-26	Procédés et compositions de prévention et de traitement de la perte d'audition
EP3185910A4 (fr)	2018-01-10	Méthodes et compositions pour le traitement du cancer
EP3491129A4 (fr)	2020-01-22	Procédés de traitement de l'osmidrose
EP3262065A4 (fr)	2018-08-01	Procédés et compositions de traitement des dystroglycanopathies
ZA201900984B (en)	2019-12-18	Methods and compositions for the treatment of warts
EP3265103A4 (fr)	2018-11-14	Compositions et méthodes de traitement de maladies oculaires
EP3206708A4 (fr)	2018-05-30	Méthodes et compositions pour le traitement de troubles liés à l'irradiation
EP3107534A4 (fr)	2017-09-06	Compositions et procédés pour le traitement de maladies neurodégénératives
EP3554494A4 (fr)	2021-02-17	Compositions et méthodes pour le traitement d'une inflammation
EP3280406A4 (fr)	2019-02-20	Compositions et méthodes de traitement de troubles du mouvement
EP3104940A4 (fr)	2017-07-26	Compositions et méthodes pour prévenir et/ou traiter une schistosomiase

Legal Events

Date	Code	Title	Description
2017-09-22	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE
2018-12-21	PUAI	Public reference made under article 153(3) epc to a published international application that has entered the european phase	Free format text: ORIGINAL CODE: 0009012
2018-12-21	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE
2019-01-23	17P	Request for examination filed	Effective date: 20180906
2019-01-23	AK	Designated contracting states	Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
2019-01-23	AX	Request for extension of the european patent	Extension state: BA ME
2019-06-26	DAV	Request for validation of the european patent (deleted)
2019-06-26	DAX	Request for extension of the european patent (deleted)
2019-11-13	A4	Supplementary search report drawn up and despatched	Effective date: 20191010
2019-11-13	RIC1	Information provided on ipc code assigned before grant	Ipc: A61K 31/439 20060101AFI20191004BHEP Ipc: A61K 47/38 20060101ALI20191004BHEP Ipc: A61P 27/10 20060101ALI20191004BHEP Ipc: A61K 9/00 20060101ALI20191004BHEP Ipc: A61K 31/4409 20060101ALI20191004BHEP
2020-10-16	STAA	Information on the status of an ep patent application or granted ep patent	Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN
2020-11-18	18D	Application deemed to be withdrawn	Effective date: 20200603